Lupus & antiphospholipid syndrome
National epidemiological analysis of lupus in Chile: A registry-based study from 2013 to 2024
Authors' conclusion
Our findings demonstrate SLE incidence rates higher than North American estimates, significant sex disparities in both incidence and mortality, and age-related mortality progression.
Study context
- Population
- Beneficiaries of Chile's Specific Health Guarantees Program (GES), July 2013 to August 2024, covering 95% of the insured population
- Exposure
- Male vs Female
- Outcome
- SLE incidence, prevalence and mortality
Methodological detailsnational, Poisson regression with population offset, sensitivity analyses
- National
- Poisson regression with population offset
- Sensitivity analyses
Main finding
As reported in the abstract
Median annual SLE incidence per 100,000 beneficiaries · 2014–2023
Median annual SLE incidence per 100,000 beneficiaries (IQR 6.3-7.7)
7.1
Observational data: associations, not effects.
Further findings
| Outcome | Rate Ratio (95% CI) | |
|---|---|---|
| Incidence by sexMale-to-female incidence ratio 1:10.61 | 0.093 (0.088–0.098) | |
| Mortality (program discharges as proxy), per 1000 SLE patients | 1.756 (1.546–1.987) | |
| 0.050.21520Rate Ratio (log scale) |
Mortality in patients ≥60 years, per 1000
- Mortality (program discharges as proxy), per 1000 SLE patients — Overall mortality rate per 1000 SLE patients (IQR 7.2-18.8)
- 11.9
SLE prevalence per 100,000
- Prevalence in 2013, per 100,000
- 26.7
- Prevalence in 2024, per 100,000
- 91.3
Sensitivity analysis: mortality assuming 70%-100% of discharges fatal
- Mortality estimates range per 1000 SLE patients
- 8.2 to 11.9
Original publication
National epidemiological analysis of lupus in Chile: A registry-based study from 2013 to 2024. Lupus. Published 16 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →